Home > Boards > US Listed > Medical - Drugs >

Auspex Pharmaceuticals, Inc. (ASPX)

Add ASPX Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 4/1/2015 8:36:38 PM - Followers: 1 - Board type: Free - Posts Today: 0

Dec 22, 2014 Auspex Added to the NASDAQ Biotechnology Index

Dec 16, 2014 Auspex Announces Positive Topline Results From Registration Trial of SD-809 for Chorea Associated With Huntington's Disease

Dec 1, 2014 Auspex to Present at the Piper Jaffray Healthcare Conference

Nov 10, 2014 Auspex Pharmaceuticals Reports Third Quarter 2014 Results and Business Highlights




Pratik Shah, PhD

President and CEO

Pratik Shah is President and CEO of Auspex. He was previously Executive Chairman of Auspex and has been involved in shaping the company's strategy since joining the board in 2007. He has been involved in a number of biotechnology companies and was lead director and founding investor in CNS Therapeutics (acquired by Mallincrodt). He represents Thomas, McNerney & Partners as a Partner on the boards of Cebix, Ocera Therapeutics, Inc. and SGB. Pratik was co-founder of biopharmaceutical company Kalypsys, Inc. Before co-founding Kalypsys, Pratik was at McKinsey & Company (San Francisco), where he focused on biotechnology and venture capital projects. He was formerly co-founder and VP of Operations at NephRx Corporation, a start-up company focused on the discovery of therapeutic proteins for renal disease. Pratik holds a BS in Biological Sciences from the University of California at Irvine and both a PhD in Biochemistry & Molecular Biology and an MBA in Finance from the University of Chicago.

John Schmid
Chief Financial Officer

John Schmid joined us as Chief Financial Officer in September 2013. Before joining us, Mr. Schmid co- founded Trius Therapeutics, Inc., a publicly-traded biopharmaceutical company, where he served as the Chief Financial Officer from June 2004 until its merger with Cubist Pharmaceuticals, Inc. in September 2013. Prior to Trius Therapeutics, Inc., Mr. Schmid served as the Chief Financial Officer at GeneFormatics, Inc., a private biotechnology company, from 1998 to 2003 and Endonetics, Inc., a private medical device company, from 1995 to 1998. Mr. Schmid also currently serves as the chairman of the board of directors of Speak, Inc., a speakers bureau, which he helped found in 1989. Mr. Schmid holds a BA in Economics from Wesleyan University and an MBA from the University of San Diego.

David Stamler, MD
Chief Medical Officer

Dr. Stamler has served as our Chief Medical Officer since January 2011. Prior to joining us, Dr. Stamler served as Senior Vice President and Chief Medical Officer at XenoPort, Inc., a publicly-traded biopharmaceutical company, from 2008 to 2010 and Chief Scientific Officer and Head of Drug Development at Prestwick Pharmaceuticals, Inc., a private pharmaceutical company, from 2005 to 2008. Prior to Prestwick Pharmaceuticals, Inc., Dr. Stamler worked at Fujisawa Pharmaceutical Co. and its subsidiaries from 1997 to 2005, in various leadership roles, including Vice President, Research and Development, Medical Sciences at Fujisawa Healthcare, Inc. from 2003 to 2005 and as Vice President, Clinical Research Center at Fujisawa Research Institute of America from 2000 to 2003. Dr. Stamler began his career at Abbott Laboratories, a publicly-traded global pharmaceuticals and healthcare products company, where he served in various positions from 1993 to 1997, including Director of Clinical Research, Pharmaceutical Products for the International Division. Dr. Stamler received an M.D. from the University of Chicago—The Pritzker School of Medicine and a BA in Biology from the University of Chicago.

Samuel Saks, MD
Chief Development Officer

Sam Saks is a board certified oncologist who was most recently the founding CEO of Jazz Pharmaceuticals until his retirement in 2009. From 2001 until he joined Jazz, Dr. Saks was company group chairman of ALZA Corporation and member of the Johnson & Johnson Pharmaceutical Operating Committee. From 1992 until 2001, he held executive positions at ALZA, including group vice president, ALZA Pharmaceuticals, where he was responsible for clinical, regulatory and commercial activities. Prior to joining ALZA, Dr. Saks held clinical research and development management positions with Schering-Plough, Xoma and Genentech. Dr. Saks has a Bachelor's degree in biology and his medical degree from the University of Illinois. He completed his residency in internal medicine at Texas Southwestern, and his fellowship in oncology at the University of California – San Francisco, and is Board certified in both specialties. Dr. Saks is a director of Auspex Pharmaceuticals, TONIX Pharmaceuticals, Depomed, Bullet Biotechnology, NuMedii and Velocity Pharmaceutical Development.

Bharatt Chowrira, PhD, JD
Chief Operating Officer

Dr. Chowrira joined us as Chief Operating Officer in October 2013. Prior to joining us, Dr. Chowrira served as President and Chief Executive Officer of Addex Therapeutics, Inc., a biotechnology company publicly-traded on the SIX Swiss Exchange, from August 2011 to May 2013. Prior to Addex Therapeutics, Inc., he served as Senior Vice President and Chief Operating Officer at Nektar Therapeutics, or Nektar, a publicly-traded clinical-stage biopharmaceutical company, from May 2008 to January 2011, during which time he also served as the chairman of the board of directors of Nektar India PTY Ltd., a wholly owned subsidiary of Nektar. Prior to Nektar, Dr. Chowrira served as the Vice President, Legal and Chief Patent Counsel at Sirna Therapeutics, Inc., a publicly-traded biotechnology company, from June 2003 until its acquisition by Merck & Co., Inc., or Merck, a publicly-traded global health care company, in December 2006, after which he stayed at Merck until May 2008 as Vice President, Sirna and Executive Director, Worldwide Licensing. From 1993 to 2003, Dr. Chowrira held various leadership positions at Sirna Therapeutics, Inc.'s predecessor, Ribozyme Pharmaceuticals, Inc., a publicly-traded biotechnology company. Dr. Chowrira received a JD from the University of Denver—Sturm College of Law, a PhD in Molecular Biology from the University of Vermont College of Medicine, an MS in Molecular Biology from Illinois State University and a BS in Microbiology from the University of Agricultural Sciences, Bangalore, India.

Andreas Sommer, PhD
Vice President

Dr. Sommer joined us as Chief Operating Officer in 2009 and became our Vice President in October 2013. Prior to joining us, Dr. Sommer served as Senior Vice President—Research and then President and Chief Executive Officer of Celtrix Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, from 1995 until it was acquired by Insmed, Inc., a biopharmaceutical company, in 2000. From 2000 to 2007, Dr. Sommer served as Chief Scientific Officer of Insmed. Prior to Celtrix Pharmaceuticals, Inc., he began his career as Vice President, Research and Development at BioGrowth, Inc., a private biotechnology company, in 1989. Dr. Sommer received his PhD in Microbiology from the University of California, Davis and an MS/BS in Technical Microbiology from the Swiss Federal Institute of Technology.

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ASPX News: Amended Statement of Beneficial Ownership (sc 13d/a) 05/28/2015 05:27:45 PM
ASPX News: Termination of Registration of a Class of Security Under Section 12(b) (15-12b) 05/15/2015 09:01:56 AM
ASPX News: Amended Statement of Ownership (sc 13g/a) 05/14/2015 04:17:18 PM
ASPX News: Statement of Changes in Beneficial Ownership (4) 05/07/2015 01:39:49 PM
ASPX News: Statement of Changes in Beneficial Ownership (4) 05/07/2015 08:57:33 AM
#29   hi, RichDude not holding this. ash111 04/01/15 08:36:38 PM
#28   Did I miss out on a major gain here? RichDude 04/01/15 07:08:43 PM
#27   BUYOUT OF AUSPEX - LAW FIRM SEEKS HIGHER PRICE tedkov 03/31/15 01:21:43 PM
#26   Hope elite pharmaceuticals is next OEFORDPARTS 03/30/15 08:37:54 PM
#25   They are DOA. No choice for RWTHEBulls$ 03/30/15 09:23:15 AM
#24   shorts are in real trouble now. ash111 03/30/15 08:29:26 AM
#23   Lol under 1bl. Well I guess RWTHEBulls$ 03/30/15 07:38:14 AM
#22   [Teva to buy Auspex in a $3.2 billion ash111 03/30/15 07:22:44 AM
#21   Bio stock is crazy anything could happen. But Stockyang 03/24/15 09:17:03 PM
#20   Good companies with good products arent even valued noobie107 03/24/15 09:05:17 PM
#19   New company with good pipeline Stockyang 03/24/15 09:02:14 PM
#18   I don't think a company with no products noobie107 03/24/15 09:00:38 PM
#17   What is going on with ASPX from last Stockyang 03/23/15 08:45:36 PM
#16   Awesome bounce from the $56.50 offering price. Called KingDMC 01/26/15 05:01:56 PM
#15   Bounce spot on! KingDMC 01/23/15 02:07:59 PM
#14   Offering price $56.50 I see a bounce from KingDMC 01/23/15 08:31:31 AM
#13   Yikes what's the offering price? KingDMC 01/21/15 06:22:27 PM
#12   More insider selling noobie107 01/13/15 09:13:34 AM
#11   I've set a target price of $37 before noobie107 12/26/14 08:38:18 PM
#10   http://www.mideasttime.com/insider-selling-auspex-pharmaceuticals-major-sharehol noobie107 12/23/14 11:55:56 AM
#9   Yessssssss keep going lower! noobie107 12/23/14 11:32:53 AM
#8   Finally a red day! Momentum needs to consolidate noobie107 12/22/14 11:57:03 AM
#7   $ASPX goes onto the Nasdaq Biotech 100 on monday. noobie107 12/20/14 01:36:14 PM
#6   $ASPX DD Notes ~ http://www.ddnotesmaker.com/ASPX stocktrademan 12/19/14 10:10:27 AM
#5   It was under the radar, like many great noobie107 12/19/14 01:04:38 AM
#4   Yeah maybe if the selling stops. Definitely some KingDMC 12/17/14 11:00:23 AM
#3   Bio plays are huge.. As soon as I Tdash 12/17/14 10:47:49 AM
#2   Great New$ looks like this can hit $55 today! Tdash 12/17/14 10:29:19 AM
#1   Typically a big fan of bio plays, how KingDMC 12/17/14 10:25:43 AM
Consent Preferences